These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 18278201)
1. Comparison of the effect of different homocysteine concentrations on clot formation using human plasma and purified fibrinogen. Marchi R; Carvajal Z; Weisel JW Thromb Haemost; 2008 Feb; 99(2):451-2. PubMed ID: 18278201 [No Abstract] [Full Text] [Related]
2. Impaired fibrin gel permeability by high homocysteine levels. Quintana IL; Oberholzer MV; Kordich L; Lauricella AM Thromb Res; 2011 Jan; 127(1):35-8. PubMed ID: 19744701 [TBL] [Abstract][Full Text] [Related]
3. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. Sauls DL; Wolberg AS; Hoffman M J Thromb Haemost; 2003 Feb; 1(2):300-6. PubMed ID: 12871504 [TBL] [Abstract][Full Text] [Related]
4. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890 [TBL] [Abstract][Full Text] [Related]
5. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting. Greenberg CS; Miraglia CC; Rickles FR; Shuman MA J Clin Invest; 1985 May; 75(5):1463-70. PubMed ID: 2860124 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of homocysteine in the reduced form, its thiolactone and protein homocysteinylation on hemostatic properties of plasma. Malinowska J; Nowak P; Olas B Thromb Res; 2011 Mar; 127(3):214-9. PubMed ID: 21186049 [TBL] [Abstract][Full Text] [Related]
7. Regulation of thrombin cleavage of plasma factor XIII bound to fibrin. Greenberg CS; Achyuthan KE; Miraglia CC; Dobson JV Ann N Y Acad Sci; 1986; 485():140-3. PubMed ID: 3471145 [No Abstract] [Full Text] [Related]
8. Fibrinogen, red blood cells, and factor XIII in venous thrombosis. Walton BL; Byrnes JR; Wolberg AS J Thromb Haemost; 2015 Jun; 13 Suppl 1(Suppl 1):S208-15. PubMed ID: 26149026 [TBL] [Abstract][Full Text] [Related]
9. The conversion of fibrinogen to fibrin: A brief history of some key events. Doolittle RF Matrix Biol; 2017 Jul; 60-61():5-7. PubMed ID: 27519977 [TBL] [Abstract][Full Text] [Related]
10. Aronia melanocarpa extract suppresses the biotoxicity of homocysteine and its metabolite on the hemostatic activity of fibrinogen and plasma. Malinowska J; Babicz K; Olas B; Stochmal A; Oleszek W Nutrition; 2012 Jul; 28(7-8):793-8. PubMed ID: 22261575 [TBL] [Abstract][Full Text] [Related]
11. Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry. Koller T; Kinast N; Castellanos AG; Garcia SP; Iglesias PP; Vintro XL; Arranz JM; Seto NV; García MVM; Moreno-Castaño AB; Aznar-Salatti J; Albaladejo GE; Diaz-Ricart M Scand J Trauma Resusc Emerg Med; 2021 Apr; 29(1):57. PubMed ID: 33836790 [TBL] [Abstract][Full Text] [Related]
12. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Nielsen VG Acta Anaesthesiol Scand; 2005 Sep; 49(8):1163-71. PubMed ID: 16095459 [TBL] [Abstract][Full Text] [Related]
13. Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Mirshahi M; Soria J; Soria C; Bertrand O; Mirshahi M; Basdevant A Thromb Res; 1987 Nov; 48(3):279-89. PubMed ID: 3124289 [TBL] [Abstract][Full Text] [Related]
14. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture. Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225 [TBL] [Abstract][Full Text] [Related]
15. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740 [TBL] [Abstract][Full Text] [Related]
16. New approaches to old problems in the clotting of fibrinogen. Lorand L Ann N Y Acad Sci; 1983 Jun; 408():226-32. PubMed ID: 6575686 [No Abstract] [Full Text] [Related]
17. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Lorand L Ann N Y Acad Sci; 2001; 936():291-311. PubMed ID: 11460485 [TBL] [Abstract][Full Text] [Related]
18. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Wettstein P; Haeberli A; Stutz M; Rohner M; Corbetta C; Gabi K; Schnider T; Korte W Anesth Analg; 2004 Nov; 99(5):1564-1569. PubMed ID: 15502066 [TBL] [Abstract][Full Text] [Related]
19. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood. Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970 [TBL] [Abstract][Full Text] [Related]
20. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Ariëns RA; Lai TS; Weisel JW; Greenberg CS; Grant PJ Blood; 2002 Aug; 100(3):743-54. PubMed ID: 12130481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]